Ardent Health vs HCA Healthcare
ARDT and HCA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARDT and HCA compare
HCA Healthcare is the larger company, worth 60 times as much as Ardent Health ($102B against $1.7B).
On earnings, HCA Healthcare is cheaper: it trades at 15.7× trailing earnings, against 21.9× for Ardent Health.
HCA Healthcare grew revenue faster over the last twelve months (5.8% versus 3.3% for Ardent Health).
HCA Healthcare keeps more of each dollar of sales as profit, with a net margin of 8.6% compared with 1.2% at Ardent Health.
HCA Healthcare pays a dividend yielding 0.65%; Ardent Health does not pay one.
HCA Healthcare scores higher on the StockData Score (10 against 8 for Ardent Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARDT | HCA |
|---|---|---|
| Size and price | ||
| Market cap | $1.7B | $102B |
| Share price | $12.03 | $473.19 |
| Change, 1 year | −19.9% | 1.0% |
| Change, 5 years | – | 90.6% |
| Beta (5Y) | 0.56 | 0.74 |
| Employees | 25K | 320K |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 4 (better) | 2 |
| Growth score | 0 | 2 (better) |
| Performance score | 2 | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 21.9× | 15.7× (better) |
| P/S | 0.3× (better) | 1.3× |
| P/B | 1.3× | – |
| EV/EBITDA | 6.6× (better) | 9.8× |
| P/FCF | – | 17.2× |
| PEG | – | 1.12 |
| FCF yield | – | 5.8% |
| Fair value | $18.80 | $480.11 |
| Margin of safety | 36.0% (better) | 1.4% |
| Growth | ||
| Revenue growth (TTM) | 3.3% | 5.8% (better) |
| Revenue growth, 5Y average | – | 8.0% |
| Net income growth (TTM) | −69.3% | 6.8% (better) |
| EPS growth (TTM) | −69.6% | 16.7% (better) |
| EPS growth, 5Y average | – | 21.0% |
| Profitability | ||
| Net margin | 1.2% | 8.6% (better) |
| FCF margin | – | 7.6% |
| Return on equity | 6.0% | – |
| Financial health | ||
| Debt / equity | 0.82 | – |
| Net debt / EBITDA | 1.01 (better) | 3.11 |
| Current ratio | 2.10 (better) | 0.82 |
| Altman Z-score | 1.89 | 1.91 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.65% |
| Payout ratio | – | 10.1% |
| Years of dividend growth | – | 5 |
| Dividend growth, 5Y average | – | 46.3% |
| Buyback yield | – | 8.9% |
| Shareholder yield | 0.00% | 9.6% (better) |
| Ownership | ||
| Held by institutions | 76.9% | 62.1% |
| Held by insiders | 78.9% | 44.4% |
| Insider net buying, 12 months | $186K (better) | −$31.1M |
| Superinvestors holding | – | 3 |
| Short interest, % of float | 15.6% | 4.1% |
Go deeper
- ARDT stock overview
- ARDT income statement
- ARDT valuation and score
- HCA stock overview
- HCA income statement
- HCA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.